OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Graff on the Use of Sacituzumab Govitecan in Breast Cancer

July 24th 2018

Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses the use of sacituzumab govitecan (IMMU-132) in breast cancer.

Dr. Lunning Discusses the Treatment of Peripheral T-Cell Lymphoma

July 23rd 2018

Matthew A. Lunning, DO, assistant professor, Internal Medicine Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the treatment of patients with peripheral T-cell lymphoma.

Dr. Holstein Discusses Induction Therapy for Multiple Myeloma

July 23rd 2018

Sarah Holstein, MD, PhD, associate professor, University of Nebraska Medical Center, discusses induction therapy for the treatment of patients with multiple myeloma.

Dr. Chi Discusses Pediatric Atypical Teratoid Rhabdoid Tumors

July 23rd 2018

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses pediatric atypical teratoid rhabdoid tumors.

Dr. Reardon on Pembrolizumab and Bevacizumab for Glioblastoma

July 23rd 2018

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses pembrolizumab (Keytruda) and bevacizumab (Avastin) for the treatment of patients with recurrent PD-L1–positive glioblastoma.

Dr. Eng Discusses Results of the PRODIGE 7 Trial

July 23rd 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses why the negative results of the PRODIGE 7 trial are beneficial moving forward.

Dr. Bekaii-Saab on Adjuvant Therapy in Pancreatic Cancer

July 21st 2018

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses adjuvant therapy in pancreatic cancer.

Dr. Agarwala on Impact of Combining Entinostat with Pembrolizumab

July 20th 2018

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of combining entinostat with pembrolizumab (Keytruda) across a number of tumor types.

Dr. Razis on Molecular Targeting of Glioblastoma

July 20th 2018

Evangelia Razis, MD, PhD, medical oncologist, Hygeia Hospital, Athens, Greece, discusses the importance of molecular targeting for patients with glioblastoma.

Dr. Mims on FDA Approval of Ivosidenib in Patients With AML

July 20th 2018

Alice Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of the IDH1m inhibitor ivosidenib for the treatment of patients with acute myeloid leukemia (AML).

Dr. Ulahannan on the VALENTINO Trial in Advanced CRC

July 20th 2018

Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the VALENTINO trial in advanced colorectal cancer (CRC).

Dr. Horn on Selecting Inhibitors for ALK+ NSCLC

July 20th 2018

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses selecting the necessary inhibitor for patients with ALK-positive non-small cell lung cancer.

Dr. O'Neil on Emerging Therapeutic Techniques in Bladder Cancer

July 20th 2018

Brock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses emerging therapeutic techniques in bladder cancer.

Dr. Shunyakov on the Impact of Next-Generation Sequencing in Oncology

July 20th 2018

Leonid Shunyakov, MD, hematologist/oncologist, Central Care Cancer Center, discusses the impact of next-generation sequencing (NGS) in oncology.

Dr. Vogelzang Discusses PROSPECT Trial for Prostate Cancer

July 20th 2018

Nicholas J. Vogelzang, MD, site research leader for Comprehensive Cancer Centers of Nevada, member of US Oncology Network, 2018 Giant of Cancer Care

Dr. Shah Highlights Immunotherapy for Esophageal Cancer

July 19th 2018

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, highlights immunotherapy for esophageal cancer.

Dr. Tewari on the Evolution of Treatment in Cervical Cancer

July 19th 2018

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the evolution of treatment in cervical cancer.

Dr. Katzel on Why Women With Head and Neck Cancer are Undertreated

July 19th 2018

Jed A. Katzel, MD, hematology, Kaiser Permanente Santa Clara Medical Center, discusses why women with head and neck cancer are undertreated.

Dr. Shafaee on the PERSEPHONE Trial in Early-Stage HER2+ Breast Cancer

July 19th 2018

Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the PERSEPHONE trial in women with early-stage HER2-positive breast cancer.

Dr. Markman on Latest Advances in Treatment of Gynecological Malignancies

July 18th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses the latest advances in treatment for gynecological malignancies and other tumor types.